LACEY WINKEL: Open Payments
NPI 1003517913 · SPANISH FORK, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$699 in 41 payments from 11 companies in 2025. Trend: 2023 $234 · 2024 $636 · 2025 $699
Food & beverage: $699
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $402 |
| Astellas Pharma US Inc | 3 | $57 |
| Lilly USA, LLC | 3 | $45 |
| Organon LLC | 4 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| SANOFI-AVENTIS U.S. LLC | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| Novo Nordisk Inc | 1 | $18 |
Products named: VRAYLAR, QULIPTA, Veozah, MOUNJARO, MAVYRET, NEXPLANON, REXULTI, TZIELD.
Industry payments across UT — which companies pay providers there.
